Max Solenthaler

3.8k total citations · 1 hit paper
29 papers, 2.7k citations indexed

About

Max Solenthaler is a scholar working on Hematology, Genetics and Immunology. According to data from OpenAlex, Max Solenthaler has authored 29 papers receiving a total of 2.7k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Hematology, 13 papers in Genetics and 10 papers in Immunology. Recurrent topics in Max Solenthaler's work include Chronic Lymphocytic Leukemia Research (6 papers), Lymphoma Diagnosis and Treatment (6 papers) and Acute Myeloid Leukemia Research (4 papers). Max Solenthaler is often cited by papers focused on Chronic Lymphocytic Leukemia Research (6 papers), Lymphoma Diagnosis and Treatment (6 papers) and Acute Myeloid Leukemia Research (4 papers). Max Solenthaler collaborates with scholars based in Switzerland, Germany and Austria. Max Solenthaler's co-authors include Miha Furlan, Bernhard Lämmle, Rodolfo Robles, Manuela Krause, Paul A. Kyrle, V. Aumann, U. Mittler, B. Brenner, Giuseppe Remuzzi and I. Scharrer and has published in prestigious journals such as New England Journal of Medicine, Blood and PLoS ONE.

In The Last Decade

Max Solenthaler

29 papers receiving 2.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

von Willebrand Factor–Cleaving Protease in Thrombotic Thrombocytopenic Purpura and the Hemolytic–Uremic Syndrome

1998 1.3k citations Miha Furlan, Rodolfo Robles et al. New England Journal of Medicine profile →

Peers

Countries citing papers authored by Max Solenthaler

Since Specialization

Citations

This map shows the geographic impact of Max Solenthaler's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Max Solenthaler with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Max Solenthaler more than expected).

Fields of papers citing papers by Max Solenthaler

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Max Solenthaler. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Max Solenthaler. The network helps show where Max Solenthaler may publish in the future.

Co-authorship network of co-authors of Max Solenthaler

This figure shows the co-authorship network connecting the top 25 collaborators of Max Solenthaler. A scholar is included among the top collaborators of Max Solenthaler based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Max Solenthaler. Max Solenthaler is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Trends of incidence and survival of patients with chronic myelomonocytic leukemia between 1999 and 2014: A comparison between Swiss and American population-based cancer registries 2019 ·Cancer Epidemiology ·(unknown), Michael Daskalakis, Anita Feller, Ulrike Bacher, (unknown), (unknown), Andreas Holbro, (unknown), Rudolf Benz, Max Solenthaler, Georg Stüssi, Volker Arndt, Nicolas Bonadies	10
2	Using Digital RNA Counting and Flow Cytometry to Compare mRNA with Protein Expression in Acute Leukemias 2012 ·PLoS ONE ·Paula Fernández, Max Solenthaler, Olivier Spertini, (unknown), Alicia Rovó, (unknown), (unknown), (unknown), (unknown), Olivier Schaad, Mylène Docquier, Patrick Descombes, Thomas Matthes, (unknown)	13
3	Immunophenotyping of acute leukemia and lymphoproliferative disorders: a consensus proposal of the European LeukemiaNet Work Package 10 2011 ·Leukemia ·Marie C. Béné, Thomas Nebe, Peter Bettelheim, Barbara Buldini, Horia Bumbea, Wolfgang Kern, Francis Lacombe, P Lemež, Iuri Marinov, Estella Matutes, Marc Maynadié, Uta Oelschlägel, (unknown), Richard Schabath, Max Solenthaler, G. Tschurtschenthaler, Ana‐Maria Vlădăreanu, Gina Zini, G Fauré, Anna Porwit	127
4	Pyrazinamide‐induced sideroblastic anemia 2011 ·American Journal of Hematology ·Giuseppe Colucci, Tobias Silzle, Max Solenthaler	7
5	Efficacy of rituximab and cladribine in patients with chronic lymphocytic leukemia and feasibility of stem cell mobilization: a prospective multicenter phase II trial (protocol SAKK 34/02) 2010 ·Leukemia & lymphoma ·Nicolas Leupin, Jan C. Schuller, Max Solenthaler, Dominik Heim, Alicia Rovó, (unknown), Michael Gregor, Mario Bargetzi, Peter Brauchli, Andreas Himmelmann, Silvia Hanselmann, (unknown)	6
6	Bulky extramedullary hematopoiesis is not a rare complication of congenital dyserythropoietic anemia 2009 ·Annals of Hematology ·H. Heimpel, Ulrich Dührsen, (unknown), (unknown), (unknown), Klaus Schwarz, Max Solenthaler, Sandra Pauls	8
7	Panzytopenie und Hämolyse - Diagnose, Differenzialdiagnose und Therapie der perniziösen Anämie 2007 ·DMW - Deutsche Medizinische Wochenschrift ·(unknown), (unknown), Max Solenthaler	1
8	The Combination of 2-CDA and Rituximab in Patients with Chronic Lymphocytic Leukemia (CLL): A Prospective Multicenter Phase II Trial (SAKK 34/02). 2007 ·Blood ·Nicolas Leupin, Jan C. Schuller, Max Solenthaler, André Tichelli, Aloïs Gratwohl, (unknown), Mario Bargetzi, Andreas Himmelmann, (unknown), (unknown)	1
9	Polysomy 8 defines a clinico-cytogenetic entity representing a subset of myeloid hematologic malignancies associated with a poor prognosis: report on a cohort of 12 patients and review of 105 published cases 2005 ·Cancer Genetics and Cytogenetics ·(unknown), Dominique Mühlematter, V. Parlier, C Cabrol, (unknown), Max Solenthaler, Andreas Tobler, P Pugin, Michael Gregor, Felicitas Hitz, U Hess, B Chapuis, (unknown), Urs Schanz, (unknown), Guy van Melle, Martine Jotterand	13
10	Splenectomy in relapsing and plasma-refractory acquired thrombotic thrombocytopenic purpura. 2004 ·PubMed ·Johanna A. Kremer Hovinga, Jan–Dirk Studt, Franziska Demarmels Biasiutti, Max Solenthaler, Lorenzo Alberio, (unknown), Stefano Fontana, Behrouz Mansouri Taleghani, Andreas Tobler, Bernhard Lämmle	48
11	Successful treatment of chemotherapy‐refractory Sézary syndrome with alemtuzumab (Campath‐1H) 2003 ·European Journal Of Haematology ·Oliver Gautschi, (unknown), Marcus R. Streit, Max Solenthaler, Thomas Hunziker, (unknown)	29
12	Congenital dyserythropoietic anaemia type II (HEMPAS) and haemochromatosis 2003 ·European Journal of Gastroenterology & Hepatology ·Johanna A. Kremer Hovinga, Max Solenthaler, Jean‐François Dufour	6
13	Intensive chemotherapy with whole blood stem-cell support and concurrent chest radiotherapy in small cell lung cancer: a phase I/II trial 2002 ·Lung Cancer ·Antonello Calderoni, Christian von Briel, Stefan Aebi, Max Solenthaler, Daniel Betticher	2
14	p53 and mdm2 in mantle cell lymphoma in leukemic phase. 2002 ·PubMed ·Max Solenthaler, Estella Matutes, Vasantha Brito‐Babapulle, Ricardo Morilla, Daniel Catovsky	20
15	Should Whole-Body Red Cell Mass Be Measured or Calculated? 2000 ·Blood Cells Molecules and Diseases ·(unknown), Max Solenthaler, Miha Furlan	21
16	Severe inclusion body β‐thalassaemia with haemolysis in a patient double heterozygous for β°‐thalassaemia and quadruplicated α‐globin gene arrangement of the anti‐4.2 type 1999 ·British Journal of Haematology ·(unknown), Max Solenthaler, Samuel Deutsch, (unknown), A Tobler, (unknown), Giulio Gabbiani	20
17	von Willebrand Factor–Cleaving Protease in Thrombotic Thrombocytopenic Purpura and the Hemolytic–Uremic Syndrome breakdown → 1998 ·New England Journal of Medicine ·Miha Furlan, Rodolfo Robles, Miriam Galbusera, Giuseppe Remuzzi, Paul A. Kyrle, B. Brenner, Manuela Krause, I. Scharrer, V. Aumann, U. Mittler, Max Solenthaler, Bernhard Lämmle	1254
18	Acquired Deficiency of von Willebrand Factor-Cleaving Protease in a Patient With Thrombotic Thrombocytopenic Purpura 1998 ·Blood ·Miha Furlan, Rodolfo Robles, Max Solenthaler, Bernhard Lämmle	265
19	Deficient Activity of von Willebrand Factor–Cleaving Protease in Chronic Relapsing Thrombotic Thrombocytopenic Purpura 1997 ·Blood ·Miha Furlan, Rodolfo Robles, Max Solenthaler, (unknown), P Sandoz, Bernhard Lämmle	417
20	Arrhythmogenic right ventricular dysplasia in identical twins 1994 ·The American Journal of Cardiology ·Max Solenthaler, Manfred Ritter, RETO CANDINAS, Rolf Jenni, Franz W. Amann	5

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact